Genmab reported DKK4.09B in Sales Revenues for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Agios Pharmaceuticals AGIO:US USD 3.52M 2.07M
Amarin AMRN:US USD 89.88M 4.56M
Amgen AMGN:US USD 6.65B 58M
Artemis Alpha ATS:LN GBP -25863000 16.53M
AstraZeneca AZN:LN USD 10.98B 211M
Bayer BAYN:GR EUR 11.28B 1.54B
Biomarin Pharmaceutical BMRN:US USD 505.34M 28.45M
Bluebird Bio BLUE:US USD 71K 1.45M
Exelixis EXEL:US USD 411.74M 7.69M
Fresenius Medical Care FME:GR EUR 5.1B 339M
Galapagos GLPG:NA EUR 148.04M 473K
Genmab GEN:DC DKK 4.09B 925M
GlaxoSmithKline GSK:LN GBP 782.9B 90B
GN Store Nord GN:DC DKK 4.7B 156M
Hikma Pharmaceutical HIK:LN USD 1.21B 124M
Immunogen IMGN:US USD 15.38M 1.21M
Insmed INSM:US USD 67.73M 2.51M
Lonza Group LONN:SW CHF 2.98B 115M
Merck MRK:GR EUR 5.81B 238M
Novartis NOVN:VX USD 12.84B 243M
Regeneron Pharmaceuticals REGN:US USD 2.94B 79M
Roche Holding ROG:VX CHF 32.3B 207M
Seattle Genetics SGEN:US USD 510.3M 12.8M
William Demant Holding WDH:DC DKK 9.5B 121M